World's Best Scientists 2026 revealed!
Matthew L. Freedman

Matthew L. Freedman

D-Index & Metrics

Genetics

D-Index
89
Citations
30627
World Ranking
1117
National Ranking
535

Medicine

D-Index
89
Citations
31684
World Ranking
12614
National Ranking
6450

Matthew L. Freedman publication distribution in Genetics in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Genetics in 2026. The highlighted bar marks where Matthew L. Freedman sits on this spectrum.

45–54 publications: 6 scientists 55–64 publications: 10 scientists 65–74 publications: 35 scientists 75–84 publications: 84 scientists 85–94 publications: 102 scientists 95–104 publications: 151 scientists 105–114 publications: 175 scientists 115–124 publications: 203 scientists 125–134 publications: 217 scientists 135–144 publications: 205 scientists 145–154 publications: 193 scientists 155–164 publications: 188 scientists 165–174 publications: 170 scientists 175–184 publications: 178 scientists 185–194 publications: 164 scientists 195–204 publications: 173 scientists 205–214 publications: 159 scientists 215–224 publications: 134 scientists 225–234 publications: 143 scientists 235–244 publications: 105 scientists 245–254 publications: 114 scientists 255–264 publications: 92 scientists 265–274 publications: 88 scientists 275–284 publications: 87 scientists 285–294 publications: 80 scientists 295–304 publications: 62 scientists 305–314 publications: 75 scientists 315–324 publications: 67 scientists 325–334 publications: 60 scientists 335–344 publications: 52 scientists 345–354 publications: 40 scientists 355–364 publications: 48 scientists 365–374 publications: 47 scientists 375–384 publications: 46 scientists 385–394 publications: 31 scientists 395–404 publications: 27 scientists 405–414 publications: 40 scientists 415–424 publications: 30 scientists 425–434 publications: 43 scientists 435–444 publications: 29 scientists 445–454 publications: 14 scientists 455–464 publications: 28 scientists 465–474 publications: 21 scientists 475–484 publications: 21 scientists 485–494 publications: 22 scientists 495–504 publications: 17 scientists 505–514 publications: 12 scientists 515–524 publications: 11 scientists 525–534 publications: 8 scientists 535–544 publications: 8 scientists 545–554 publications: 14 scientists 555–564 publications: 4 scientists 565–574 publications: 11 scientists 575–584 publications: 5 scientists 585–594 publications: 11 scientists 595–604 publications: 12 scientists 605–614 publications: 7 scientists 615–624 publications: 6 scientists 625–634 publications: 10 scientists 635–644 publications: 9 scientists 645–654 publications: 10 scientists 655–664 publications: 6 scientists 665–674 publications: 6 scientists 675–684 publications: 6 scientists 685–694 publications: 4 scientists 695–702 publications: 6 scientists 703+ publications: 100 scientists
45 publications 703+

This scientist: 312 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 703 publications or more.

Matthew L. Freedman D-index placement in Genetics in 2026

The chart shows the D-index (discipline H-index) distribution of Genetics scientists ranked by Research.com in 2026. The highlighted bar marks where Matthew L. Freedman sits on this spectrum.

40–41 D-Index: 24 scientists 42–43 D-Index: 52 scientists 44–45 D-Index: 84 scientists 46–47 D-Index: 112 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 141 scientists 52–53 D-Index: 143 scientists 54–55 D-Index: 145 scientists 56–57 D-Index: 179 scientists 58–59 D-Index: 162 scientists 60–61 D-Index: 175 scientists 62–63 D-Index: 191 scientists 64–65 D-Index: 172 scientists 66–67 D-Index: 184 scientists 68–69 D-Index: 164 scientists 70–71 D-Index: 158 scientists 72–73 D-Index: 150 scientists 74–75 D-Index: 136 scientists 76–77 D-Index: 127 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 111 scientists 82–83 D-Index: 110 scientists 84–85 D-Index: 110 scientists 86–87 D-Index: 84 scientists 88–89 D-Index: 102 scientists 90–91 D-Index: 66 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 70 scientists 96–97 D-Index: 54 scientists 98–99 D-Index: 60 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 55 scientists 104–105 D-Index: 45 scientists 106–107 D-Index: 42 scientists 108–109 D-Index: 28 scientists 110–111 D-Index: 39 scientists 112–113 D-Index: 25 scientists 114–115 D-Index: 31 scientists 116–117 D-Index: 29 scientists 118–119 D-Index: 34 scientists 120–121 D-Index: 29 scientists 122–123 D-Index: 29 scientists 124–125 D-Index: 18 scientists 126–127 D-Index: 27 scientists 128–129 D-Index: 22 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 11 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 12 scientists 138–139 D-Index: 21 scientists 140–141 D-Index: 4 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 14 scientists 146–147 D-Index: 6 scientists 148–149 D-Index: 10 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 9 scientists 154–155 D-Index: 8 scientists 156–157 D-Index: 8 scientists 158–159 D-Index: 9 scientists 160+ D-Index: 96 scientists
40 D-Index 160+

This scientist: 89 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 160 D-Index or more.

Overview

Matthew L. Freedman is affiliated with Harvard University in the United States. Their research spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine, with a focus on several subfields including Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research, Oncology, and Genetics.

The scientist's work extensively covers multiple main topics, reflecting a concentrated interest in prostate and renal cancers as well as cancer genomics. The primary topics include:

  • Prostate Cancer Treatment and Research
  • Epigenetics and DNA Methylation
  • Cancer Genomics and Diagnostics
  • Renal cell carcinoma treatment
  • Genomics and Chromatin Dynamics
  • Genetic Associations and Epidemiology
  • PARP inhibition in cancer therapy

Matthew L. Freedman has co-authored with several frequent collaborators, indicating ongoing research partnerships. Notable co-authors include:

  • Sylvan C. Baca
  • Ji-Heui Seo
  • Mark M. Pomerantz
  • Toni K. Choueiri
  • Jacob E. Berchuck

The scientist regularly publishes in various academic venues, with a particular concentration in:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Clinical Oncology
  • Nature Communications
  • Cancer Research
  • Zenodo (CERN European Organization for Nuclear Research)

Selected recent papers demonstrate an emphasis on prostate cancer genomics, epigenetics, and diagnostic methods. These include:

  • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019, 2020, Journal of Clinical Oncology
  • Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes, 2020, Nature Medicine
  • Prostate cancer reactivates developmental epigenomic programs during metastatic progression, 2020, Nature Genetics
  • EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer, 2021, Nature Cancer
  • Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer, 2021, Nature Communications

Best Publications

  • Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement

    Julian Little;Julian P.T. Higgins;John P.A. Ioannidis;John P.A. Ioannidis;David Moher

  • Assessing the impact of population stratification on genetic association studies.

    Matthew L Freedman;Matthew L Freedman;David Reich;David Reich;Kathryn L Penney;Kathryn L Penney;Gavin J McDonald;Gavin J McDonald

  • Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.

    Pu Liu;Susan A. Tarlé;Amitav Hajra;David F. Claxton

  • A full genome search in multiple sclerosis

    G C Ebers;K Kukay;D E Bulman;A D Sadovnick

  • Multiple regions within 8q24 independently affect risk for prostate cancer.

    Christopher A Haiman;Nick Patterson;Matthew L Freedman;Matthew L Freedman;Simon R Myers

  • The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.

    Mark M. Pomerantz;Nasim Ahmadiyeh;Nasim Ahmadiyeh;Li Jia;Paula Herman

  • Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men

    Matthew L. Freedman;Christopher A. Haiman;Nick Patterson;Gavin J. McDonald;Gavin J. McDonald

  • PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

    G Francis;R Hughes;J King;P Mitchell

  • A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer

    Ali Amin Al Olama;Zsofia Kote-Jarai;Sonja I. Berndt;David V. Conti

  • Demonstrating stratification in a European American population.

    Catarina D Campbell;Elizabeth L Ogburn;Kathryn L Lunetta;Helen N Lyon;Helen N Lyon

  • Principles for the post-GWAS functional characterization of cancer risk loci

    Matthew L Freedman;Alvaro N A Monteiro;Simon A Gayther;Simon A Gayther;Gerhard A Coetzee

  • 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC

    Nasim Ahmadiyeh;Mark M. Pomerantz;Chiara Grisanzio;Paula Herman

  • The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis

    Mark M Pomerantz;Fugen Li;David Y Takeda;David Y Takeda;Romina Lenci

  • Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction

    Eric J. Topol;Jeanette McCarthy;Stacey Gabriel;David J. Moliterno

  • Integrative eQTL-Based Analyses Reveal the Biology of Breast Cancer Risk Loci

    Qiyuan Li;Ji Heui Seo;Barbara Elaine Stranger;Aaron McKenna;Aaron McKenna

  • Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer

    John K. Gohagan;Pamela M. Marcus;Richard M. Fagerstrom;Paul F. Pinsky

  • Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals.

    Daniel O. Stram;Celeste Leigh Pearce;Phillip Bretsky;Matthew Freedman

  • A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer

    David Y. Takeda;David Y. Takeda;Sándor Spisák;Ji Heui Seo;Connor Bell

  • Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus

    Li Jia;Gilad Landan;Mark Pomerantz;Rami Jaschek

  • STrengthening the REporting of Genetic Association studies (STREGA)

    Julian Little;{Julian P. T} Higgins;{John P. A} Ioannidis;David Moher

Frequent Co-Authors

Christopher A. Haiman
Christopher A. Haiman University of Southern California
Toni K. Choueiri
Toni K. Choueiri Harvard University
Peter Kraft
Peter Kraft Harvard University
Kathryn L. Penney
Kathryn L. Penney Harvard University
Brian E. Henderson
Brian E. Henderson University of Southern California
David J. Hunter
David J. Hunter Harvard University
Alexander Gusev
Alexander Gusev Dana-Farber Cancer Institute
Daniel O. Stram
Daniel O. Stram University of Southern California
Paul D.P. Pharoah
Paul D.P. Pharoah University of Cambridge
Stephen J. Chanock
Stephen J. Chanock National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Genetics is a rapidly evolving field with many interdisciplinary career options. For those interested in healthcare, exploring related online degrees can open doors to dynamic pathways in patient care, administration, and research. Importantly, the flexibility of online degrees makes them accessible to a wide range of students, whether you are starting your career or looking to advance.

If you’re drawn to clinical roles, you might consider fast track LPN programs, which allow you to enter the workforce quickly through flexible online learning. Those seeking to bypass standardized testing can look for nursing schools that don't require teas, making the entry process less stressful. For leadership and administrative positions, an affordable master's in healthcare administration can provide the skills you need to manage teams and healthcare facilities effectively.

If research or academics appeal to you, consider a PhD in nursing online program to develop high-level expertise. Each of these career paths complements a background in genetics and can help you make a meaningful impact in health sciences.

Best Scientists Citing Matthew L. Freedman

Trending Scientists